Arenavirus genome rearrangement for the development of live attenuated vaccines

Journal of Virology

Volumn 89, Issue 14, 2015, Pages 7373-7384

  Cheng, Benson Yee Hin ^a   Ortiz Riaño, Emilio ^a   De La Torre, Juan Carlos ^b   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; TRANSFER RNA; VIRUS RNA; VIRUS VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARENAVIRUS INFECTION; ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE LOCUS; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS INFECTION; MALE; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES TRANSLOCATION; VIRAL GENETICS; VIRUS GENOME; VIRUS STRAIN; ANIMAL; ARENAVIRIDAE INFECTIONS; C57BL MOUSE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTIC CHORIOMENINGITIS; PHYSIOLOGY; REVERSE GENETICS; SURVIVAL; VIRUS CULTURE; VIRUS REPLICATION;

ARENAVIRIDAE; ARENAVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS;

ANIMALS; ARENAVIRIDAE INFECTIONS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENES, REPORTER; GENOME, VIRAL; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MALE; MICE, INBRED C57BL; REVERSE GENETICS; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84931024342     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00307-15     Document Type: Article

References (68)

1. Buchmeier MJ, de la Torre JC, Peters CJ. 2007. Arenaviridae: the viruses and their replication, p 1791-1827. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol II. Lippincott Williams & Wilkins, Philadelphia, PA, USA.
2. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287: 2391-2405. http://dx.doi.org/10.1001/jama.287.18.2391.
3. McCormick JB, Fisher-Hoch SP. 2002. Lassa fever. Curr Top Microbiol Immunol 262:75-109.
4. CDC. 4 April 2014. Lassa fever reported in U.S. traveler returning from West Africa. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/media/releases/2014/p0404-lassa-fever.html.
5. Holmes GP, McCormick JB, Trock SC, Chase RA, Lewis SM, Mason CA, Hall PA, Brammer LS, Perez-Oronoz GI, McDonnell MK, Paulissen JP, Schonberger LB, Fisher-Hoch SP. 1990. Lassa fever in the United States. Investigation of a case and new guidelines for management.NEngl J Med 323:1120-1123.
6. Kitching A, Addiman S, Cathcart S, Bischop L, Krahe D, Nicholas M, Coakley J, Lloyd G, Brooks T, Morgan D, Turbitt D. 2009. A fatal case of Lassa fever in London, January 2009. Euro Surveill 14:pii=19117. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19117.
7. Hirabayashi Y, Oka S, Goto H, Shimada K, Kurata T, Fisher-Hoch SP, McCormick JB. 1989. The first imported case of Lassa fever in Japan. Nihon Rinsho 47:71-75. (In Japanese.).
8. Kerber R, Reindl S, Romanowski V, Gomez RM, Ogbaini-Emovon E, Gunther S, Ter Meulen J. 18 December 2014, posting date. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps. J Clin Virol http://dx.doi.org/10.1016/j.jcv.2014.12.004.
9. Fichet-Calvet E, Rogers DJ. 2009. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 3:e388. http://dx.doi.org/10.1371/journal.pntd.0000388.
10. Delgado S, Erickson BR, Agudo R, Blair PJ, Vallejo E, Albarino CG, Vargas J, Comer JA, Rollin PE, Ksiazek TG, Olson JG, Nichol ST. 2008. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 4:e1000047. http://dx.doi.org/10.1371/journal.ppat.1000047.
11. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, Khristova ML, Weyer J, Swanepoel R, Egholm M, Nichol ST, Lipkin WI. 2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5:e1000455. http://dx.doi.org/10.1371/journal.ppat.1000455.
12. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Comer JA, Guarner J, Paddock CD, DeMeo DL, Shieh WJ, Erickson BR, Bandy U, DeMaria A, Jr, Davis JP, Delmonico FL, Pavlin B, Likos A, Vincent MJ, Sealy TK, Goldsmith CS, Jernigan DB, Rollin PE, Packard MM, Patel M, Rowland C, Helfand RF, Nichol ST, Fishman JA, Ksiazek T, Zaki SR; LCMV in Transplant Recipients Investigation Team. 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 354:2235-2249. http://dx.doi.org/10.1056/NEJMoa053240.
13. Palacios G, Druce J, Du L, Tran T, Birch C, Briese T, Conlan S, Quan PL, Hui J, Marshall J, Simons JF, Egholm M, Paddock CD, Shieh WJ, Goldsmith CS, Zaki SR, Catton M, Lipkin WI. 2008. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 358:991-998. http://dx.doi.org/10.1056/NEJMoa073785.
14. Schafer IJ, Miller R, Stroher U, Knust B, Nichol ST, Rollin PE. 2014. Notes from the field: a cluster of lymphocytic choriomeningitis virus infections transmitted through organ transplantation-Iowa, 2013. Am J Transplant 14:1459. http://dx.doi.org/10.1111/ajt.12802.
15. Barton LL, Mets MB, Beauchamp CL. 2002. Lymphocytic choriomeningitis virus: emerging fetal teratogen. Am J Obstet Gynecol 187:1715-1716. http://dx.doi.org/10.1067/mob.2002.126297.
16. Charrel RN, de Lamballerie X. 2003. Arenaviruses other than Lassa virus. Antiviral Res 57:89-100. http://dx.doi.org/10.1016/S0166-3542(02)00202-4.
17. Kilgore PE, Ksiazek TG, Rollin PE, Mills JN, Villagra MR, Montenegro MJ, Costales MA, Paredes LC, Peters CJ. 1997. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 24:718-722. http://dx.doi.org/10.1093/clind/24.4.718.
18. McKee KT, Jr, Huggins JW, Trahan CJ, Mahlandt BG. 1988. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother 32:1304-1309. http://dx.doi.org/10.1128/AAC.32.9.1304.
19. Snell N. 1988. Ribavirin therapy for Lassa fever. Practitioner 232:432.
20. Bausch DG, Hadi CM, Khan SH, Lertora JJ. 2010. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 51:1435-1441. http://dx.doi.org/10.1086/657315.
21. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martin V. 2011. Ribavirin can be mutagenic for arenaviruses. J Virol 85:7246-7255. http://dx.doi.org/10.1128/JVI.00614-11.
22. Maiztegui JI, McKee KT, Jr, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, Levis SC, Ambrosio AM, Halsey NA, Peters CJ. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 177: 277-283. http://dx.doi.org/10.1086/514211.
23. Emonet SF, Seregin AV, Yun NE, Poussard AL, Walker AG, de la Torre JC, Paessler S. 2011. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J Virol 85:1473-1483. http://dx.doi.org/10.1128/JVI.02102-10.
24. Contigiani M, Medeot S, Diaz G. 1993. Heterogeneity and stability characteristics of Candid 1 attenuated strain of Junin virus. Acta Virol 37:41-46.
25. Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon PM. 2011. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol 85:13457-13462. http://dx.doi.org/10.1128/JVI.05616-11.
26. Albariño CG, Bird BH, Chakrabarti AK, Dodd KA, Flint M, Bergeron E, White DM, Nichol ST. 2011. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J Virol 85:10404-10408. http://dx.doi.org/10.1128/JVI.00856-11.
27. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Stroher U, Fernando L, Daddario KM, Guttieri MC, Mothe BR, Larsen T, Hensley LE, Jahrling PB, Feldmann H. 2005. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2:e183. http://dx.doi.org/10.1371/journal.pmed.0020183.
28. Auperin DD, Esposito JJ, Lange JV, Bauer SP, Knight J, Sasso DR, McCormick JB. 1988. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res 9:233-248. http://dx.doi.org/10.1016/0168-1702(88)90033-0.
29. Clegg JC, Lloyd G. 1987. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet ii:186-188.
30. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Stroher U. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78:5458-5465. http://dx.doi.org/10.1128/JVI.78.10.5458-5465.2004.
31. Lukashevich IS. 2012. Advanced vaccine candidates for Lassa fever. Viruses 4:2514-2557. http://dx.doi.org/10.3390/v4112514.
32. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. 2000. Effective vaccine for Lassa fever. J Virol 74:6777-6783. http://dx.doi.org/10.1128/JVI.74.15.6777-6783.2000.
33. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS. 2005. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79:13934-13942. http://dx.doi.org/10.1128/JVI.79.22.13934-13942.2005.
34. Carrion R, Jr, Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, Salvato MS, Lukashevich IS. 2007. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25:4093-4102. http://dx.doi.org/10.1016/j.vaccine.2007.02.038.
35. Lukashevich IS, Carrion R, Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, Bryant J, Davis H, Hammamieh R, Mayda M, Jett M, Patterson J. 2008. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26:5246-5254. http://dx.doi.org/10.1016/j.vaccine.2008.07.057.
36. Zapata JC, Goicochea M, Nadai Y, Eyzaguirre LM, Carr JK, Tallon LJ, Sadzewicz L, Myers G, Fraser CM, Su Q, Djavani M, Lukashevich IS, Salvato MS. 2014. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. J Virol 88:3058-3066. http://dx.doi.org/10.1128/JVI.03035-13.
37. Cottone R, Buttner M, Bauer B, Henkel M, Hettich E, Rziha HJ. 1998. Analysis of genomic rearrangement and subsequent gene deletion of the attenuated Orf virus strain D1701. Virus Res 56:53-67. http://dx.doi.org/10.1016/S0168-1702(98)00056-2.
38. Navarro A, Trask SD, Patton JT. 2013. Generation of genetically stable recombinant rotaviruses containing novel genome rearrangements and heterologous sequences by reverse genetics. J Virol 87:6211-6220. http://dx.doi.org/10.1128/JVI.00413-13.
39. de Haan CA, Volders H, Koetzner CA, Masters PS, Rottier PJ. 2002. Coronaviruses maintain viability despite dramatic rearrangements of the strictly conserved genome organization. J Virol 76:12491-12502. http://dx.doi.org/10.1128/JVI.76.24.12491-12502.2002.
40. Wu X, Rupprecht CE. 2008. Glycoprotein gene relocation in rabies virus. Virus Res 131:95-99. http://dx.doi.org/10.1016/j.virusres.2007.07.018.
41. Lowen AC, Boyd A, Fazakerley JK, Elliott RM. 2005. Attenuation of bunyavirus replication by rearrangement of viral coding and noncoding sequences. J Virol 79:6940-6946. http://dx.doi.org/10.1128/JVI.79.11.6940-6946.2005.
42. Flanagan EB, Ball LA, Wertz GW. 2000. Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J Virol 74:7895-7902. http://dx.doi.org/10.1128/JVI.74.17.7895-7902.2000.
43. Flanagan EB, Zamparo JM, Ball LA, Rodriguez LL, Wertz GW. 2001. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75:6107-6114. http://dx.doi.org/10.1128/JVI.75.13.6107-6114.2001.
44. Krempl C, Murphy BR, Collins PL. 2002. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol 76:11931-11942. http://dx.doi.org/10.1128/JVI.76.23.11931-11942.2002.
45. Pena L, Sutton T, Chockalingam A, Kumar S, Angel M, Shao H, Chen H, Li W, Perez DR. 2013. Influenza viruses with rearranged genomes as live-attenuated vaccines. J Virol 87:5118-5127. http://dx.doi.org/10.1128/JVI.02490-12.
46. Perez M, Craven RC, de la Torre JC. 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci USA 100:12978-12983. http://dx.doi.org/10.1073/pnas.2133782100.
47. Lee KJ, Novella IS, Teng MN, Oldstone MB, de La Torre JC. 2000. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol 74:3470-3477. http://dx.doi.org/10.1128/JVI.74.8.3470-3477.2000.
48. Ortiz-Riaño E, Cheng BY, de la Torre JC, Martínez-Sobrido L. 2011. The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the type I interferon response. J Virol 85:13038-13048. http://dx.doi.org/10.1128/JVI.05834-11.
49. Groseth A, Wolff S, Strecker T, Hoenen T, Becker S. 2010. Efficient budding of the Tacaribe virus matrix protein z requires the nucleoprotein. J Virol 84:3603-3611. http://dx.doi.org/10.1128/JVI.02429-09.
50. Martínez-Sobrido L, Zúñiga EI, Rosario D, García-Sastre A, de la Torre JC. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 80:9192-9199. http://dx.doi.org/10.1128/JVI.00555-06.
51. Martínez-Sobrido L, Giannakas P, Cubitt B, García-Sastre A, de la Torre JC. 2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol 81:12696-12703. http://dx.doi.org/10.1128/JVI.00882-07.
52. Martínez-Sobrido L, Emonet S, Giannakas P, Cubitt B, García-Sastre A, de la Torre JC. 2009. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 83:11330-11340. http://dx.doi.org/10.1128/JVI.00763-09.
53. Pythoud C, Rodrigo WW, Pasqual G, Rothenberger S, Martinez-Sobrido L, de la Torre JC, Kunz S. 2012. Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKepsilon. J Virol 86:7728-7738. http://dx.doi.org/10.1128/JVI.00187-12.
54. Rodrigo WW, Ortiz-Riano E, Pythoud C, Kunz S, de la Torre JC, Martinez-Sobrido L. 2012. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J Virol 86:8185-8197. http://dx.doi.org/10.1128/JVI.07240-11.
55. Borrow P, Martinez-Sobrido L, de la Torre JC. 2010. Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses 2:2443-2480. http://dx.doi.org/10.3390/v2112443.
56. Perez M, de la Torre JC. 2003. Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 77:1184-1194. http://dx.doi.org/10.1128/JVI.77.2.1184-1194.2003.
57. Auperin DD, Romanowski V, Galinski M, Bishop DH. 1984. Sequencing studies of Pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral S RNA. J Virol 52:897-904.
58. Ortiz-Riaño E, Cheng BY, Carlos de la Torre J, Martínez-Sobrido L. 2013. Arenavirus reverse genetics for vaccine development. J Gen Virol 94(Pt 6):1175-1188. http://dx.doi.org/10.1099/vir.0.051102-0.
59. Cheng BY, Ortiz-Riano E, de la Torre JC, Martinez-Sobrido L. 1 August 2013, posting date. Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells. J Vis Exp http://dx.doi.org/10.3791/50662.
60. Emonet SE, Urata S, de la Torre JC. 2011. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 411:416-425. http://dx.doi.org/10.1016/j.virol.2011.01.013.
61. Emonet SF, Garidou L, McGavern DB, de la Torre JC. 2009. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci USA 106:3473-3478. http://dx.doi.org/10.1073/pnas.0900088106.
62. Flatz L, Bergthaler A, de la Torre JC, Pinschewer DD. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci USA 103:4663-4668. http://dx.doi.org/10.1073/pnas.0600652103.
63. Cheng BY, Ortiz-Riaño E, Nogales A, de la Torre JC, Martínez-Sobrido L. 14 January 2015. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol http://dx.doi.org/10.1128/JVI.03401-14.
64. Cecchini N, Schmerer M, Molineux IJ, Springman R, Bull JJ. 2013. Evolutionarily stable attenuation by genome rearrangement in a virus. G3 (Bethesda) 3:1389-1397. http://dx.doi.org/10.1534/g3.113.006403.
65. Wertz GW, Perepelitsa VP, Ball LA. 1998. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci USA 95:3501-3506. http://dx.doi.org/10.1073/pnas.95.7.3501.
66. Ball LA, Pringle CR, Flanagan B, Perepelitsa VP, Wertz GW. 1999. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73:4705-4712.
67. Jin H, Lu B, Zhou H, Ma C, Zhao J, Yang CF, Kemble G, Greenberg H. 2003. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306:18-24. http://dx.doi.org/10.1016/S0042-6822(02)00035-1.
68. Seregin AV, Yun NE, Miller M, Aronson J, Smith JK, Walker AG, Smith JN, Huang C, Manning JT, de la Torre JC, Paessler S. 25 March 2015. The glycoprotein precursor gene of Junin virus determines the virulence of the Romero strain and the attenuation of the Candid #1 strain in a representative animal model of Argentine hemorrhagic fever. J Virol http://dx.doi.org/10.1128/JVI.00104-15.